Argus Investors Counsel’s Boston Scientific BSX Stock Holding History

Argus Investors Counsel’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-25,712	Closed	-$1.61M	–	108
2026 Q1	$1.61M	Sell	25,712 -1,060	-4%	-$84.8K	1.43%	23
2025 Q4	$2.55M	Sell	26,772 -23	-0.1%	-$2.25K	2.04%	19
2025 Q3	$2.62M	Sell	26,795 -68	-0.3%	-$7.04K	2.08%	19
2025 Q2	$2.89M	Buy	26,863 +415	+2%	+$42K	2.05%	16
2025 Q1	$2.67M	Buy	26,448 +96	+0.4%	+$9.67K	2.03%	14
2024 Q4	$2.35M	Sell	26,352 -443	-2%	-$39K	1.57%	19
2024 Q3	$2.25M	Buy	26,795 +6,621	+33%	+$522K	1.46%	21
2024 Q2	$1.55M	Buy	+20,174	New	+$1.48M	0.95%	34

Other funds holding BSX

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Milford Funds Auckland $6.14B AUM

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

Banque Transatlantique Paris, France $4.66B AUM 33.26% 1-Year Est. Return

Argus Investors Counsel's BSX Position: Q2 2026 in Review

Argus Investors Counsel sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 25,712 shares — an estimated $1.61M sold.

Argus Investors Counsel first reported a position in BSX in Q2 2024 and held it in 8 quarters. The position peaked at $2.89M in Q2 2025. 534 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Argus Investors Counsel reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Argus Investors Counsel sold 25,712 Boston Scientific shares in Q2 2026, an estimated $1.61M.
Argus Investors Counsel first reported a position in Boston Scientific in Q2 2024 and held it in 8 quarters.
Argus Investors Counsel's Boston Scientific position peaked at $2.89M in Q2 2025.
534 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Argus Investors Counsel's 13F filing for Q2 2026, filed 31 Jul 2026.